Featured News


Emerging Sources of Early-Stage Life Science Funding Embrace the Role of ‘Venture Catalysts’

MEDCITY

It was nice to hear one healthcare executive and investor after another respond to the question, “what are your key priorities when evaluating a deal?” with the answer, “really compelling science.”

I’ve often heard VCs and angel investors cite the importance of large addressable markets and talented executive teams as key considerations to a deal, along with compelling technology. But the different dynamics among different investors really came to the surface at today’s Life Science Nation’s Redefining Early-Stage Investments conference in Boston, which focused on alternative sources of funding…

Read More